Ranbaxy CEO Says Purchase By Daiichi Not Threatened By Investigation
This article was originally published in PharmAsia News
The acquisition of Ranbaxy Laboratories by Daiichi Sankyo is still on track and cannot legally be derailed, according to the Indian firm's CEO. Malvinder Singh said his counterparts at Daiichi were aware the U.S. FDA had questions about some of Ranbaxy's generic drugs before the agency's investigation became public. Singh addressed a news conference in the wake of speculation the merger of the two giants might be scuttled by FDA's questions. He said there was no doubt the $4.6 billion deal was still alive. Daiichi confirmed the sale is final. (Click here for more - a subscription may be required
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.